Immuron (NASDAQ:IMRN) Posts Earnings Results

Immuron (NASDAQ:IMRN) released its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $1.40 million during the quarter.

Immuron Trading Down 3.8%

IMRN traded down $0.03 during midday trading on Friday, reaching $0.79. 18,285 shares of the company’s stock traded hands, compared to its average volume of 35,990. The firm has a fifty day moving average of $0.81 and a two-hundred day moving average of $1.13. Immuron has a 52 week low of $0.68 and a 52 week high of $2.39.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immuron in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Investors Weigh In On Immuron

An institutional investor recently bought a new position in Immuron stock. Citadel Advisors LLC bought a new position in Immuron (NASDAQ:IMRN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned about 0.29% of Immuron at the end of the most recent quarter. Institutional investors own 0.12% of the company’s stock.

About Immuron

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.